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Long-term kidney transplant outcomes have reached mild improvements recently.
Parietal epithelial cells (PECs) are progenitor cells located along the Bowman’s capsule
that can be isolated in urine, and display the capability to replace podocytes, but in
certain situations cause glomerulosclerosis. In this study, a cohort of stable kidney
transplant recipients with 6 months protocol biopsy was divided in two groups
depending on the presence (uPEC+; n = 41) or absence (uPEC-; n = 25) of PECs
in urine and followed for 2 years. No differences were found between groups at 6
months after transplantation considering clinical variables, alloimmune response, renal
function, albuminuria and graft pathology. However, uPEC+ group showed increased
podocyturia and a higher rate of proliferating PECs along the Bowman’s capsule, without
concomitant enhancement of the CD44 pro-sclerotic activation marker. Accordingly,
2 years follow up evidenced poorer outcomes in the uPEC+ group with worse renal
function, increased albuminuria, wider mesangial expansion and more severe IFTA.
In summary, chronic allograft damage can progress in certain stable-supposed grafts
by podocyte detachment and reactive PECs proliferation, being the uPEC presence a
biomarker of this process. This damage-response regenerative process, if sustained in
time, might fail in preserve the allograft function and histology. Our study raises new
prospects to overcome current limits on long-term allograft results.
Keywords: parietal epithelial cells, kidney transplantation, podocyte detachment, graft outcomes, estimated
glomerular filtration rate, albuminuria
INTRODUCTION
Chronic kidney disease is a leading cause of morbidity and mortality nowadays, with a renal
replacement therapy (RRT) prevalence of 924 patients per million population in Europe (Pippias
et al., 2017). Kidney transplantation is the RRT option that offers the best outcomes in terms of
life expectancy and quality of life (Wolfe et al., 1999). In this sense, new approaches are needed
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to improve graft function and survival especially considering
long-term outcomes, where clinical advances have been subtle in
the last years (Meier-Kriesche et al., 2004; Nankivell and Kuypers,
2011; Riella et al., 2016).
Many studies have been performed focusing on the
mechanisms of kidney graft damage, especially on ischemia-
reperfusion injury, alloimmunity, nephrotoxicity and disease
recurrence (Briganti et al., 2002; Menke et al., 2014; Bamoulid
et al., 2015), but little is known about the own mechanisms the
kidney uses to compensate these damages and the potential
regenerative processes behind.
The recently identified progenitor cell population surrounding
the Bowman’s capsule displays a multipotent capacity of
differentiation into kidney specific cells terminally differentiated
(podocytes and tubular cells), which are characterized by the co-
expression of two species- specific markers, CD133 and CD24
(Sagrinati et al., 2006). These Parietal Epithelial Cells (PECs)
exhibit the capacity to ameliorate acute kidney damage (Lasagni
et al., 2015), but in certain conditions these cells might contribute
to crescent formation (Sicking et al., 2012) or glomerulosclerosis
by characteristically de novo expression of CD44 (Smeets et al.,
2011) or by undergoing epithelial to mesenchymal transition
(Naito et al., 2014).
PECs are eliminated in urine in certain physiological and
pathological conditions and have already been used to perform
functional and genotypic studies without the need of invasive
procedures (Achenbach et al., 2008; Lazzeri et al., 2015; Arcolino
et al., 2016).
Investigations on kidney allograft deterioration are mainly
focused on mechanism of allograft damage without considering
their opponents, the intrinsic mechanisms of kidney repair.
Among such mechanisms, PECs may have a relevant role on
modulating the impact of any injury.
Therefore, in our study we evaluated the presence of PECs
in the urine of a cohort of stable kidney transplant recipients
at 6 months after transplantation in order to elucidate its
association with pathological findings (Haas et al., 2014) in
protocol biopsies as well as immunological (Bestard et al., 2013)
and non-immunological mechanism of allograft damage. We
then investigated the association of PECs in the urine with
kidney allograft function and pathology at 2 years after kidney
transplantation.
We consider regeneration the cornerstone of novel kidney
transplant care, raising potential new prospects for future
prognostic features and therapeutic targets.
MATERIALS AND METHODS
Study Population and Urine Samples
This is a prospective cohort study approved by Bellvitge Hospital
Institutional Review Board (approval reference PR075/12). After
written informed consent, kidney transplant recipients with
stable renal function were prospectively included in the study
from 2013 to 2015 at 6 months after transplantation, at the
time of hospitalization due to the surveillance biopsy procedure
according to our regular clinical practice. Sample contamination,
defined as visual fungi or bacterial overgrowth in cell culture
within 24–72 h, was an exclusion criterion. Patients were followed
for 2 years when a second kidney allograft biopsy was planned.
Standardized Protocol for the Isolation
and Purification of Urine Parietal
Epithelial Cells
Urine samples were treated with Penicillin-Streptomycin
Solution (Biological Industries, Cromwell, CT, United States)
at 1:100 dilution, and then were centrifuged at 1500 rpm for
10 min as previously described (Lazzeri et al., 2015). The
supernatant was carefully removed, and the cell pellet was
washed with PBS (Dulbecco’s PBSLinus, Sigma-Aldrich, St.
Louis, MO, United States) and centrifuged again at 1500 rpm
for 5 min. The supernatant was then removed and the cell
pellet was plated in 6-well dishes with EGM-MV media
(Lonza Sales Ltd.) supplemented with 20% FBS (Hyclone
Laboratories, South Logan, UT, United States) and antibiotics
(Pen-Strep + rifampicin). Twenty-four hours after the culture,
medium was changed in order to remove all the unattached
cells and other detritus. Only cells attached to culture plates
were tributary to study. After the 1st week it was possible to
identify by optical microscopy attached cells, which achieved
80% confluence in about 2–3 weeks. It was possible to marginally
identify other attached cell types like fibroblasts or podocytes.
Medium was changed twice a week, and no cell passaging was
performed. In order to confirm their clonogenicity, control cells
were cloned and maintained in culture without incidences, and
it was possible to expand them and perform different culture
passages kept in undifferentiated state.
Fluorescence Activated Cell Sorting
At 80% confluence, adherent cells were removed from 6-well
plates (35 mm diameter) by incubation in 0.05% trypsin–
EDTA (Life Technologies, Bleiswijk, Netherlands) at 37◦C, and
were subjected to Fluorescence Activated Cell Sorting (FACS)
at passage 0 in order to specifically select those cells positive
for glyCD133 and CD24. For all experiments, the cells were
stained with CD24-PE (ML5, BD Pharmigen, San Diego, CA,
United States) and CD133-APC (clone 293C3, MiltenyiBiotec
monoclonal) antibodies for 30 min at room temperature.
Unstained cells and FMO (fluorescence minus one), treated in
the same way, were used as negative control in each experiment
and served as autofluorescence control. The control isotypes
used were for CD133 mouse IgG2b-APC (clone IS6–11E5.11)
(MiltenyiBiotec GmbH), and for CD24 mouse IgG1-FITC (clone
IS5–21F5) (BD Pharmigen, San Diego, CA, United States). Cell
death was evaluated using DAPI staining (D9542-1MG, Sigma-
Aldrich, St. Louis, MO, United States). Cells were filtered through
a 40 µm strainer to eliminate all remaining cell clumps. Sorting
was done using a MoFloAstrios cell sorter (Beckman–Coulter)
equipped with a 100 µm flow tip and operated at a sheath
pressure of 25 psi. Initially, dead cells and debris were gated
on a two physical parameter dot plot (FSC/SSC) followed by
the exclusion of doublets by using pulse processing (FSC-H
vs. FSC-A). Dead cells were excluded (DAPI+). Finally, the
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CD133 + CD24 + subpopulation was gated. An average sorting
rate of 500–1000 events per second was maintained Cells were
>98% pure after sorting. All sorted cells were frozen in dry pellet
and stored in 100,000 cells vials at−80◦C until use.
Urinary Parietal Epithelial Cells in vitro
Characterization and Differentiation
Urinary PECs (uPECs) obtained from cell sorting were kept in
culture at 1st passage in order to perform differentiation into
terminal renal cells to confirm their multipotent capacity. As
previously described (Lazzeri et al., 2015) for the differentiation
toward the tubular lineage, uPECs (n = 5) were cultured in
the tubular differentiating medium renal epithelial cell growth
medium (Lonza Sales Ltd.) supplemented with 50 ng/mL
of hepatocyte growth factor (Peprotech, Rocky Hill, NJ,
United States) for 21 days. For the differentiation toward
podocytes, uPECs (n = 5) were cultured in the podocyte-
differentiating medium VRAD, composed of DMEM/F12
(Sigma-Aldrich, St. Louis, MO, United States) supplemented
with 10% FBS (Hyclone), 100 nM vitamin D3, and 100 mM
retinoic acid, for 48 h (all from Sigma-Aldrich, St. Louis,
MO, United States). Confocal microscopy was performed on
differentiated and non-differentiated cells to identify podocyte,
tubular and cytoskeleton markers. The following antibodies were
used for the detection of tubular antigens: anti-Aquaporin1 (H-
55, Santa Cruz Biotechnology, Santa Cruz, CA, United States),
anti-LTA (Fluorescein Vector Laboratories, Burlingame, CA,
United States), anti-DBA LTA (Rhodamine, Vector Laboratories,
Burlingame, CA, United States). Podocyte markers were Anti-
Podocin (NPHS2, Abcam, Cambridge, United Kingdom),
Anti-Podocalyxin (PDLX, R&D Systems, Canada). Cytoskeleton
staining was performed with Alexa Fluor 555 Phalloidin
(Molecular Probes from Invitrogen). To-pro-3 iodide (642/661
Molecular Probes Invitrogen detection Technologies) was
used for counterstaining nuclei. Secondary antibodies included
for AQP1 Alexafluor 488 goat anti rabbit (Invitrogen), for
NPHS2 Alexafluor 488 goat anti rabbit (Invitrogen) and for
PODXLAlexafluor 488 goat anti mouse (Invitrogen).
Kidney Allograft Biopsies
Protocol biopsies were taken at 6 and 24 months after kidney
transplantation, where two core samples were obtained under
ultrasound guidance. There were no major complications related
to the procedure. Renal slices were fixed in 10% (vol./vol.)
formalin and embedded in paraffin. Histological cross sections
of 3 µm thickness were stained with haematoxylin and
eosin, periodic acid–Schiff and Masson’s trichrome for optical
microscopy assessment. The biopsies were blindly evaluated by a
pathologist (Dr. Gomà) using the Banff 2013 classification (Haas
et al., 2014).
The CD133 staining was performed with CD133/2 (293c3)
APC monoclonal mouse anti human (1:2.5; MilenyiBiotec,
Germany), with secondary antibody goat anti-mouse IgG2b-
488 (Invitrogen, Alexa Fluor) and evaluated by confocal
immunofluoresence. CD44 antibody was monoclonal
mouse anti human (1:100; 156-3c11, Abcam, Cambridge,
United Kingdom), with goat anti-mouse IgG2A HRP (Novus
Biologicals, Abingdon Oxon, United Kingdom), and evaluated
by immunohistochemistry. We evaluated the Bowman’s capsule
epithelium and the glomerular tuft, counting the number of
CD44+ cells and then calculating the mean of CD44+ cells
per glomerulus. Immunohistochemistry was also performed for
Ki67 (1:20; BD Pharmingen, San Diego, CA, United States).
We counted positive cells on Bowman’s capsule epithelium and
glomerular tuft, normalized by the total glomerulus number in
the sample.
Clinical and Analytical Data
Donor demographics were evaluated including age and gender,
as well as its characteristics being living or deceased donor, and
extended criteria donors (ECD: age 60 years or older, or over 50
years with at least two of the following conditions: hypertension
history, serum creatinine >1.5 mg/dL or cause of death from
cerebrovascular event). Variables evaluated from the recipient
included: age, gender, end-stage renal disease (ESRD) etiology,
time in dialysis, residual urinary volume, human leucocyte
antigen (HLA) mismatches, anti-HLA antibodies (Panel Reactive
antibodies >20%) and biological relation between donor and
recipient. Variables related to the transplantation procedure
included cold ischemia time and history of delayed graft function
(defined as the need of hemodialysis during the first 7 days
after kidney transplantation). Regarding immunosuppression
protocols, basiliximab was used for regular recipients and
thymoglobulin in high-immunological-risk and ECD recipients.
We considered high-immunological risk recipients those that
had lost a previous graft due to immunological reasons during
the 1st year after transplantation, those with any anti-HLA
donor specific antibody and those with a cytotoxic panel
reactive antibody (PRA) > 20%. Steroids, calcineurin inhibitors
(tacrolimus in 64 patients), and mycophenolate mofetil were
given to all patients. Maintained immunosupression treatment
at surveillance biopsy time-point included steroid withdrawal
(n = 5) and conversion from mycophenolate mofetil to
mTOR inhibitors (n = 5). Analytical data considered estimated
Glomerular Filtration Rate (measured with CKD-EPI formula),
proteinuria and albuminuria at 3, 6 months, 1 and 2 years after
transplantation, tacrolimus average levels, vitamin D levels and
glycemia at the biopsy moment. Clinical variables were recorded
including body mass index (BMI), body surface area (BSA, by
Dubois formula), hypertension and diabetes diagnosed at the
time of the 6 months biopsy, as well as history of acute rejection
events. Blood pressure measurements at 6 months after kidney
transplantation were determined after 10 min rest and with three
measures, using the median value of them for analysis. In case
of white coat effect, home blood pressure monitoring was used.
Concomitant medications as renin-angiotensin system blockers
and other anti-hypertensive drugs, insulin and oral antidiabetic
drugs, and vitamin D supplements were recorded.
Immunological Data
Immunological tests considered the presence of circulating
anti-HLA class I and II alloantibodies, performed in banked
serum samples prior to kidney transplant and at 6 months
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after it (at the moment surveillance biopsy was performed).
Antibody specificities against both class I and II HLA antigens
were determined using single-antigen flow beads assays on a
Luminex platform (Lifecodes, Division of Immucor, Stanford,
CT, United States). All beads showing a normalized MFI > 1500
MFI were considered positive if (MFI/(MFI lowest bead))> 5.
Peripheral blood mononuclear cells (PBMCs) were obtained
in heparinized tubes from renal transplant patients pre-
transplantation and at the time of 6 months protocol biopsy.
Donor cells were harvested before transplantation from donor
spleens or peripheral blood samples in deceased or living
donors, respectively. PBMCs and splenocytes were isolated by
standard Ficoll density gradient centrifugation and were frozen
in liquid nitrogen for subsequent use in the IFN-γ ELISPOT
assays.
Donor-specific (d-s) IFN-γ ELISPOT assays were performed
following recently described standard operating procedures
(SOP) (Bestard et al., 2013). Briefly, 3 × 105 responder cells
were placed in triplicate wells with 3 × 105 CD2-depleted
splenocytes (Easysep R© Human CD2 Selection kit, StemCell,
France) or CD3-depleted living-donor PBMCs (human CD3+
Cell Depletion Cocktail, RosetteSep R© kit, StemCell, France).
Recipient cells were stimulated with complete medium alone
(RPMI 1640, GE Healthcare Life Sciences, United States, with
10% inactivated FBS, antibiotics and L-glutamine) and Pokeweed
(AID, Autoimmune Diagnostika) as negative and positive
controls, respectively. Results were given as frequencies of IFN-
γ producing d-s T-cells/3× 105 PBMCs, subtracting responses of
the negative control wells.
Gene Expression Profile
It was previously described that PECs obtained from urine
exhibit an almost identical transcriptome compared to those
obtained from kidney tissue (Lazzeri et al., 2015). We then
performed Quantitative real-time PCR to selected molecules
that might suffer changes in kidney damage conditions for
PECs, like CXCL12, that mediates stem cell niche maintenance
through its receptors by homing and differentiating PECs in
kidney damage, TLR2 that plays a role in the activation,
proliferation rate and differentiation of PECs by autocrine
signaling. We also analyzed collagen IV and αSMA to evaluate
extracellular matrix production and Epithelial-to-Mesenchymal
transition, CD44 for glomerulosclerotic pattern. Vascular cell
adhesion molecule 1 also as progenitor cell commitment
pattern, Wnt7b has a specific role in controlling renal
morphogenesis and in tubule recovery by activating Wnt
signaling pathways.
For Quantitative real-time PCR, RNA was extracted from
kidney (n = 3) and urine (n = 8) PECs with Pure Link RNA
Mini Kit (Invitrogen, CA, United States), using a Trizol reagent
(Invitrogen, CA, United States) to lyse the tissues, chloroform to
separate the organic and aqueous phase (where the RNA remains)
and the ethanol to purify the RNA. RNA purity was analyzed
on a NanoDrop (NanoDrop ND-1000V3.3, Wilmington, DE,
United States) and was considered pure when the absorbance
ratio 260/280 nm was higher than 1.80. A total amount of
50 ng RNA was used to perform the reverse transcription
using a High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Warrington, United Kingdom). Thermal cycling
conditions were 10 min at 25◦C, 120 min at 37◦C, 5 min at 85◦C
and finally held at 4◦C. Tissue and uPECs expression levels of
CXCL-12, TLR-2, COL-IV, α-SMA, CD44, VCAM, and Wnt7b
were quantified by TaqMan real-time PCR (ABI Prism 7700,
Applied Biosystems, Waltham, MA, United States) using the
comparative 2−11Ct method (Applied Biosystems).
Urinary Human Podocin Quantification
Urine samples were collected from all patients included in the
study. Samples were selected and centrifuged for 30 min at
3000 g, and supernatant was properly aliquoted and stored
at −80◦C. Quantitative assessment of Podocin (OKEH00672)
protein was carried out in urine samples by enzyme-linked
immunosorbent assay (ELISA) (Aviva Systems Biology, San
Diego, CA, United States) following the manufacturer’s
recommended instructions. Quantification of human Podocin
was calculated using the standard curve.
Statistics
Continuous variables with normal or symmetrical distribution
were reported as mean and standard deviation above and
below the mean. The categorical variables were described with
frequencies and percentages. The differences between the two
groups for continuous variables were analyzed using Student’s
t-test or the Wilcoxon rank-sum test, as appropriate. The
differences between categorical variables were analyzed using the
chi-squared distribution and Fisher’s exact test, as appropriate.
ANCOVA was performed to evaluate the relationship between
a variable and a covariate. All statistical tests were considered
significant if the p-value was <0.05 for two-tailed tests. The
statistical analysis was performed with the Stat View SAS
program.
RESULTS
Isolation of Parietal Epithelial Cells From
Urine of Kidney Allograft Recipients
After written informed consent, we included 107 patients
prospectively in whom 6 months protocol biopsy was performed
and urine samples were collected, where uPEC isolation protocol
was performed (Figure 1). In 41 out of 66 patients, it was possible
to identify single flat body epithelial cells growing into clusters in
a rose shape manner from the 1st week after plating, as uPECs
were undetectable by cytospins directly from urine due to its low
number. These cells achieved a confluence of 80% in 35 mm
diameter plates at 2–3 weeks after culture and more than 98%
co-expressed CD133+CD24+ (Figure 2A).
Cultured uPECs Exhibit Phenotypical and
Genotypical Characteristics of Renal
Progenitors
Urinary CD133+CD24+ cells were negative for podocyte
(podocin, podocalyxin) and tubular epithelial cell (aquaporin
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FIGURE 1 | Flow diagram of the study population. We included stable kidney allograft recipients at 6 m after transplantation when a protocol kidney biopsy was
performed. Over 66 graft biopsies, there were 11 missing values due to no representative sample (n = 7) or other complications (n = 4). Patients were then classified
according presence of absence of uPECs and followed for 2 years.
1, LTA, DBA) markers visualized by confocal microscopy.
To evaluate the multipotency of uPECs into terminal kidney
cells, uPECs were cultured under differentiation medium and
evaluated by confocal microscopy. After differentiation into
podocytes they expressed markers such as podocin (NPHS2)
and podocalyxin (PODXL), with a characteristic sun shape
on the cytoskeleton phalloidin evaluation. When differentiated
into tubular cells, they expressed aquaporin 1 (AQP1) and
DBA (Figure 2B). Although in a previous study we described
that PECs obtained from urine exhibit an almost identical
transcriptome compared to those obtained directly from kidney
tissue (Lazzeri et al., 2015), we sought to further compare uPECs
and kidney PECs gene expression profile regarding molecules
related to stem cell recruitment, proliferation and activation
(CXCL-12, TLR-2), pro-sclerotic and fibrotic pattern molecules
(CD44, COL-IV, and α-SMA) and progenitor cell commitment
patterns (VCAM, Wnt7b). Notably, no significant differences
were found comparing PECs isolated from urine and kidney
PECs (Figure 2C).
No Donor and Transplant Recipient
Characteristics Are Found to Be
Associated to the Presence of uPECs at
6 Months After Transplantation
We then assessed whether the isolation of uPECs was associated
with some donor or recipient baseline characteristics. As showed
in Table 1, no associations were found. Pointedly, no significant
differences were evidenced regarding immunosuppression
therapy, neither in induction (basiliximab or ATG) nor in
maintenance therapy.
Moreover, no differences were observed in key outcome
variables such as acute rejection, delayed graft function,
proteinuria, albuminuria and the renal function achieved at
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FIGURE 2 | Characterization of urinary Parietal epithelial cells. (A) Phenotypical characteristics of uPECs (a′) Optical microscopy image of representative sample of
20 days cultured uPECs, in its characteristic rose-shape manner, at 400×. (a′′) Flow cytometry analysis, with CD133+ CD24+ subpopulation gated. (B) Functional
and phenotypical characteristics of uPECs. Representative confocal microscopy uPEC cultures before and after differentiation into Podocytes and Tubular Cells;
scale bar = 25 µm. (b′) Expression of podocyte markers (podocin, podocalixin) before (day 0) and after (day 2) differentiation medium VRAD (n = 5). (b′′) Expression
of tubular markers (aquaporin- 1, DBA) before (day 0) and after (day 21) differentiation medium ECGM (n = 5). Every cell type cytoskeleton was evaluated by
phalloidin staining. DAPI counter stains nuclei (blue). One representative sample is shown over five samples processed for each differentiation. (C) mRNA expression
profile comparing uPECs to renal tissue PECs. For Quantitative real-time PCR, PECs RNA was extracted from kidney (n = 3) and urine (n = 8) PECs with Pure Link
RNA Mini Kit (Invitrogen, CA, United States). p = NS by Mann–Whitney test.
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TABLE 1 | Kidney transplant baseline characteristics.
uPEC+ uPEC- P-value
n = 41 n = 25
Donor type (D/L) 26/15 14/11 0.61
Donor age (yr) 51.2 ± 13.4 54.5 ± 9.0 0.27
Donor gender (M/F) 25/16 12/13 0.32
Recipient age (years) 48.2 ± 13.6 53.5 ± 9.4 0.09
Recipient gender (M/F) 31/10 14/11 0.11
BMI (kg/m2) 25.5 ± 5.0 26.8 ± 4.8 0.33
Dialysis time (m) 19.2 ± 27.8 19.5 ± 23.8 0.96
Cause of ESRD 5 2 0.69
Diabetes 8 8
Glomerular disease 7 1
Hereditary 8 5
Hypertension 7 5
Interstitial 6 4
Unknown
Previous transplant (Y/N) 5/36 6/19 0.46
HLA mismatch 3.8 ± 1.4 3.6 ± 1.4 0.66
AntiHLA Ab (POS/NEG) 7/34 8/17 0.27
HLA-DSA (POS/NEG) 1/40 0/25 0.99
T-cell ELISPOT 52 ± 55 55 ± 57 0.86
Induction (BAS/ATG) 31/10 18/7 0.78
D, deceased; L, living; M, male; F; female; BMI, body mass index; ESRD, end stage
renal disease; HLA, human leukocyte antigen; Ab, antibody; DSA, donor specific
antibody.
6 m after kidney transplantation (Table 2). Also, no significant
differences were found considering hypertension, neither in
terms of prevalence nor in median values of systolic and diastolic
blood pressure, obesity, diabetes and serum calcidiol levels
(Table 2). The use of different therapies such as insulin, oral
antidiabetics, vitamin D supplementation, and the number of
anti-hypertensive drugs required and specifically ACE inhibitors
(only five patients were receiving this treatment) were also similar
between the uPEC + and uPEC- groups. All patients were
under a CNI-based regimen, without significant differences in
the average tacrolimus level achieved (uPEC+ 6.2 ng/mL; uPEC-
6.32ng/mL, p = 0.79).
Immunological Monitoring and
Histological Evaluation According to
Presence or Absence of uPECs
Immunological response against the allograft was evaluated by
assessing peripheral B and T-cell alloreactivity and kidney graft
pathology. We evaluated the presence of circulating anti-HLA
class I and II alloantibodies, donor specific antibodies and also
the presence of memory T-cells (Bestard et al., 2013) prior
to kidney transplantation and at 6 months thereafter and no
significant differences were found depending on the presence
or absence of uPECs (Tables 1, 2). Six-months graft biopsies
showed no significant histological changes on separate items
(Table 3), occurring one episode of subclinical rejection in each
group (type IA on negative uPEC group, IIB on uPEC + group)
and borderline changes in 6 patients. No differences on chronic
TABLE 2 | Significant data and outcomes at 6 months after kidney transplantation.
uPEC+ uPEC- P-value
n = 41 n = 25
DGF (Y/N) 7/34 3/22 0.73
Acute rejection (Y/N) 3/38 0/25 0.28
Corticosteroids (Y/N) 38/3 23/2 0.99
Hypertension (Y/N) 18/23 7/18 0.29
RAS Blockade (Y/N) 4/37 1/24 0.64
BMI (kg/m2) 25.8 ± 4.7 27.2 ± 4.5 0.25
Diabetes (Y/N) 6/35 5/20 0.11
Calcidiol (ng/mL) 56.8 ± 26.4 40.0 ± 20.1 0.25
Vitamin D/VDRA (Y/N) 13/28 8/17 0.99
eGFR (CKD-EPI) mL/min/1.73 m2 56.0 ± 16.5 59.3 ± 19.1 0.47
Proteinuria (g/mol) 16.1 ± 12.7 13.2 ± 13.4 0.38
Albuminuria (g/mol) 7.1 ± 10.2 3.3 ± 5.8 0.11
HLA-DSA (Y/N) 3/38 2/23 0.55
T-cell ELISPOT 28 ± 70 20 ± 19 0.62
DGF, delayed graft function; RAS, renin angiotensin system; BMI, body mass index;
VDRA, vitamin D receptor agonist; eGFR, estimated glomerular filtration rate; HLA-
DSA, human leukocyte antigen-donor specific antibodies.
TABLE 3 | Kidney allograft histology according to Banff items in 6 months
protocol biopsies.
uPEC+ uPEC- P-value
n = 39 n = 23
ag (0/1/2/3) 35/4/0/0 21/1/1/0 0.312
ai (0/1/2/3) 33/6/0/0 15/7/0/1 0.138
at (0/1/2/3) 31/6/1/1 18/2/3/0 0.313
ti (0/1/2/3) 26/13/0/0 12/10/0/1 0.299
ptc (0/1/2/3) 38/0/1/0 23/0/0/0 0.433
av (0/1/2/3) 38/0/1/0 23/0/0/0 0.433
aah (0/1/2/3) 32/6/1/0 20/2/1/0 0.695
cg (0/1/2/3) 38/1/0/0 22/1/0/0 0.377
ci (0/1/2/3) 28/10/1/0 16/6/1/0 0.935
ct (0/1/2/3) 29/9/1/0 16/7/0/0 0.642
cv (0/1/2/3) 35/3/1/0 19/3/1/0 0.514
mm (0/1/2/3) 36/3/0/0 20/1/2/0 0.164
C4d (POS/NEG) 2/37 0/23 0.526
renal lesions were found considering also glomerular sclerosis,
mesangial expansion, and IFTA. Two cases showed C4d positive
staining without other antibody mediated rejection (ABMR)
feature, both in the uPEC + group. Three patients developed de
novoDSA at 6 m without ABMR changes on the biopsy (2 of them
from uPEC- group). No differences between groups were found
related neither to immunoglobulin’s deposition, and no cases of
disease recurrence were evidenced.
CD133+ PECs From Bowman’s Capsule
Express CD44 Independently of uPEC
Isolation
We confirmed by immunofluorescence on 6 months protocol
graft biopsies that PECs expressed the characteristic CD133+
marker all along the Bowman’s capsule (Figure 3A). To evaluate
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FIGURE 3 | Immunophenotypic glomerular characterization and urinary Podocin at 6 months protocol biopsies. (A) Representative glomerular pictures on
glomerulosclerosis evaluation, where no differences in glomerular lesions were found between groups; localization of PECs surrounding the Bowman’s capsule by
CD133 + immunofluorescence; CD44 and Ki67 expressing cells evaluated along the Bowman capsule and the glomerular tuft; magnification 400×, scale
bar = 50 µm (n = 22 for uPEC-, and n = 36 for uPEC +) (B) CD44 expression per glomerular profile was not different between groups (n = 22 for uPEC-, and n = 36
for uPEC+, p = NS); (C) no differences in Ki67 expression per glomerular profile were found (p = NS); (D) In uPEC+ group Ki67 was significantly increased in PECs
along the Bowman’s capsule (p = 0.04). (E) Urinary podocin was significantly higher in the uPEC + group (p = 0.04). ∗p < 0.05.
if these cells were activated according to previously described
(Smeets et al., 2014), we performed CD44 staining in paraffin
slides from all biopsies, showing no significant differences
between uPEC+ and uPEC- groups (p = 0.26) (Figure 3B).
The Presence of uPECs Is Associated
With PECs Proliferation in the Bowman’s
Capsule and With Podocyturia
We evaluated the presence of glomerular proliferating cells
by the Ki67 marker that states active phases of the cell cycle
by immunochemistry in graft biopsies (Wharram et al., 2005;
Andeen et al., 2015; Nishizono et al., 2017). The number of
Ki67+ PECs along Bowman’s capsule per glomerular profile was
significantly increased in graft biopsies of uPEC+ compared to
those uPEC- patients (Figure 3C). Of note, no differences were
found in Ki67 expression in the glomerular tuft (Figure 3D).
Podocyte loss was evaluated by assessing the concentration
of urinary podocin (UPod) (Yang et al., 2015; Gilani et al.,
2017) at the time of the biopsy. Interestingly, the uPod was
significantly higher in the uPEC+ than in the uPEC- group
(Figure 3E).
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The Presence of uPECs at 6 Months
After Kidney Transplantation Is
Associated With eGFR Decline,
Albuminuria, and Glomerulosclerosis at 2
Years After Kidney Transplantation
We performed a 2 years follow-up of the patients included in
the study, when a second protocol biopsy was performed. One
patient was lost at follow-up and another died due to sudden
death, both in the uPEC+ group. Thus, 64 out of 66 cases were
available for the 2 years analysis.
As showed in Figure 4, the uPEC+ group displayed a
significantly lower eGFR and higher proteinuria and albuminuria
at 2 years. In concrete, mean eGFR was 51.05 mL/min in
uPEC + patients vs. 60.0 mL/min in uPEC- ones (p = 0.04).
After adjustment for baseline (6 months) eGFR, the 2 years eGFR
difference between uPEC+ and uPEC- groups was 8.95 mL/min
and remained statistically significant (p = 0.01). Moreover, higher
proteinuria and albuminuria was evidenced in the uPEC+
group (uPEC+ patients 15.4 g/mol vs. 2.1 g/mol in uPEC-
ones, p = 0.03) at 2 years than the uPEC- group. Indeed, the
values of albuminuria at 6 and 12 months after transplantation
were normal in most patients either from uPEC+ or uPEC-
group. However, at 2 years the proportion of patients with
albuminuria was 17.4% in uPEC- and 48% in uPEC+ (p = 0.03).
Results evaluated after adjusting for baseline albuminuria remain
statistically significant.
These results were in concordance with the histological
findings observed in the available 24 months protocol biopsies
(Table 4). Indeed, uPEC+ patients showed more mesangial
matrix expansion (mm Banff score was significantly higher in
uPEC+ group, p = 0.035) (Table 4) and IgM deposition (70%
in uPEC+ group, compared to 20% deposition in uPEC- group,
p = 0.025) (Figure 5A). No cases of primary glomerular disease
recurrence were evidenced.
TABLE 4 | Kidney allograft histology according to Banff items in 24 months
protocol biopsies.
uPEC+ uPEC- P-value
n = 11 n = 11
ag (0/1/2/3) 9/2/0/0 8/3/0/0 0.611
ai (0/1/2/3) 7/3/1/0 8/2/1/0 0.875
at (0/1/2/3) 8/3/2/0 9/1/1/0 0.822
ti (0/1/2/3) 6/3/2/0 7/3/1/0 0.851
ptc (0/1/2/3) 10/1/0/0 10/1/0/0 1.000
av (0/1/2/3) 11/0/0/0 11/0/0/0 1.000
aah (0/1/2/3) 6/3/2/0 6/3/0/0 0.319
cg (0/1/2/3) 11/0/0/0 11/0/0/0 1.000
ci (0/1/2/3) 4/4/3/0 5/6/0/0 0.173
ct (0/1/2/3) 3/6/1/1 4/7/0/0 0.528
cv (0/1/2/3) 7/3/1/0 9/2/0/0 0.484
mm (0/1/2/3) 6/5/0/0 11/0/0/0 0.035
C4d (POS/NEG) 0/11 0/11 1.000
Finally, we evaluated if PEC proliferation was maintained
or predominant activated PECs were present at 24 months
after transplantation. Similar results emerged regarding
CD44 expression, where no differences were found between
groups (Figure 5B). A tendency of increased proliferation
(Ki67+) on the Bowman’s capsule from uPEC+ patients was
evidenced compared to uPEC- group (Figure 5C), while no
proliferative differences were found in the glomerular tuft
(Figure 5D).
DISCUSSION
Progressive kidney transplant attrition has become a difficult
obstacle to overcome, as no significant improvements have been
achieved in the last years. In this sense, new approaches are
FIGURE 4 | Estimated glomerular filtration rate and albuminuria evolution. Evaluation performed at 6 months, 1 and 2 years in uPEC+ and uPEC- groups. A
significant decline in graft function (p = 0.04) (A) and increased albuminuria (p = 0.03) (B) is evidenced in the uPEC+ group at long-term follow up. ∗p < 0.05.
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FIGURE 5 | Evaluation of 24 months protocol biopsies. (A) An increased extracellular matrix deposition is evidenced in the uPEC+ group evaluated by PAS analysis
and also a significant deposition of IgM in a glomerular focal and segmental pattern (p = 0.025); magnification 400×, scale bar = 50 µm. (B) CD44 expression per
glomerular profile was similar between groups, as well as along the Bowman’s capsule. (C) A tendency of increased proliferation assessed by Ki67 along the
Bowman’s capsule is still evidenced, while no differences are found in proliferation in the glomerular tuft (D).
needed (Nankivell and Kuypers, 2011). Besides immunological
issues, the inner repair graft capacity could be a game changer in
generating new hypothesis and therapeutic targets. Actually, the
study of parietal epithelial cells (PECs) in kidney transplantation
may open new prospects in terms of kidney adaptation and
damage response.
In our study, we demonstrated for a first time that kidney
allograft PECs are excreted and can be isolated from the urine in a
subgroup of stable kidney transplant recipients at 6 months after
transplantation independently to demographic and transplant
characteristics, and without association to alloimmune effector
T and B cell mechanisms. The presence of PECs in the urine 6
months after transplantation was associated with podocyte loss
and glomerular PEC proliferation in the allograft and what is
more important, with poor graft outcome as demonstrated by
eGFR decline, proteinuria and chronic allograft damage after 2
years follow-up.
Based on our previous experience in uPEC isolation (Lazzeri
et al., 2015) we tried to ascertain whether uPECs were present
in the urine after kidney transplantation. During the 1st week
after transplantation PECs were always present in the urine
(personal unpublished data), probably as an organ response to
overcome ischemia and reperfusion injury. Of note, no PECs
were isolated from residual diuresis prior to transplantation,
ruling out the native kidneys as a source of these cells in patients
with ESRD. Therefore, we then investigated the presence of
uPECs at the time of 6 months protocol biopsy. We hypothesized
that in stable kidney allograft recipients the presence of uPECs
could be related with classical mechanisms of allograft damage
(Yang et al., 2015; Riella et al., 2016; Vanhove et al., 2017).
However, no differences were found between uPEC positive and
negative patients at cell isolation time point regarding renal
function, albuminuria, histological reports and even activation
of immune T and B cell responses. This finding modifies
previous observations suggesting that it was only possible to
isolate uPECs in proteinuric patients (Arcolino et al., 2016)
and opens a new focus of study in the field of kidney
transplantation. Nevertheless, and differently to patients with
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glomerulonephritis where the magnitude of the damage is larger
resulting in a higher amount of cell loss (Achenbach et al.,
2008), the number of cells excreted in urine is very low and
uncountable by cytospins, requiring cell culture expansion for
analysis.
After we were able to isolate these cells from the
urine of stable kidney allograft recipients we sought to
determine their functional characteristics. Previous studies
demonstrated that these uPECs maintained in culture their
clonogenicity and their renal fate in vitro as compared to
tissue isolated PECs (Lazzeri et al., 2015). Therefore, we
confirmed their multilineage differentiation potential, and
no previous commitment was observed (de novo expression
of podocyte and tubular cell markers after differentiation
was evidenced). Moreover, as previously reported (Lazzeri
et al., 2015) we found that gene expression profile regarding
some stem cell recruitment, proliferation, activation, pro-
fibrotic and progenitor cell commitment molecules were
similar in uPECs and PECs isolated directly from kidney
tissue.
Two lines of evidence have been assigned to PECs on
glomerular cell balance, supporting a pro-sclerotic vs. a
regenerative pattern. On one hand, it was reported that
PECs migrate onto the glomerular tuft and participate in
glomerular scar formation by extracellular matrix deposition,
characteristically proliferating and expressing the activation
marker CD44 (Smeets et al., 2014; Roeder et al., 2017), and
this was also confirmed in focal segmental glomerulosclerosis in
allograft human biopsies (Fatima et al., 2012). On the other hand,
different acute podocyte damage models demonstrate disease
amelioration concurrent to activation and differentiation of PECs
toward podocytes (Lasagni et al., 2015). Taken together, aberrant
activated PECs might induce crescents and glomerulosclerosis,
but in a situation of podocyte damage might turn into favorable
disposition by differentiation into podocytes (Hakroush et al.,
2014).
As we did not find any clinical, immunological and
histological variable associated with the presence of uPECs at
6 months after kidney transplantation, we tried to characterize
PEC features in our cohort of stable patients. Based on previous
studies (Fatima et al., 2012; Holderied et al., 2015), we analyzed
the sclerosing response from PECs on graft biopsies by staining
with the activation marker CD44 and compared extracellular
matrix deposition and Banff items for chronic lesions at 6 months
protocol biopsies, where we found no differences between groups.
Thus, our findings cannot support a direct mechanism of damage
from activated PECs in a stable kidney graft. Moreover, as
previously pointed out, these results were also supported by gene
expression profile, where no significant differences were found
between uPECs and PECs obtained from kidney tissue in terms
of CD44, αSMA nor collagen IV expression. On the other hand,
we observed a significantly increased PEC proliferation in kidney
allograft biopsies from patients displaying uPECs. Actually, cell
cycle activation determined by Ki67 expression on PECs, and
not in the glomerular tuft, from 6 m protocol graft biopsies was
higher in the uPEC+ than in the uPEC- group. As these uPECs
did not significantly differ to those PECs isolated from kidney
tissue regarding the expression of CXCL-12, TLR-2, nor Wnt7b,
other pathways might be involved in this cell niche activation.
This major finding connecting kidney PECs proliferation and
uPECs isolation could be explained because such cells undergo
cell cycle activation in order to transdifferentiate and migrate
into the glomerular tuft directly from the Bowman’s capsule
across the urinary space (Appel et al., 2009; Hackl et al., 2013;
FIGURE 6 | The presence of uPEC in stable kidney transplant recipients anticipates eGFR decline, albuminuria and glomerulosclerosis. Apart from alloimmune
damage and glomerular disease recurrence, pathophysiologic mechanisms of chronic allograft damage occur in certain stable-supposed kidney grafts, progressing
along critical steps with (1) podocyte stress and detachment, (2) glomerular rearrangement, (3) PECs proliferation and migration into the glomerular tuft, with uPECs
as a novel biomarker of this process, (4) subsequent mesangial expansion and extracellular matrix deposition. This damage-response regenerative process, if
sustained in time, might fail in preserve allograft function, and is translated into worse long-term results with eGFR decline, a significant albuminuria appearance, and
chronic glomerular histological lesions.
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Hakroush et al., 2014). This mechanism may justify their
excretion and further isolation in urine.
However, this scenario did not explain the foremost PEC
activation trigger. Therefore, we tested the hypothesis that an
underlying podocyte detachment should be present (Hakroush
et al., 2014). Podocyte loss was assessed by urinary podocin (Zhai
et al., 2016) and it was significantly associated with the presence of
uPECs at 6 months. Interestingly, this state could not be predicted
by the pathologic evaluation of the protocol biopsies nor by renal
function, proteinuria or immunological effector mechanisms,
raising a new approach of podocyte stress (Fulladosa et al., 2003;
Kriz and Lemley, 2015). Compensatory glomerular hypertrophy
is developed due to reduced nephron number in transplanted
kidneys, what directly correlates to allograft outcomes (Fulladosa
et al., 2003; Wiggins et al., 2005). Furthermore, it has been
recently reported that transplant glomerulopathy is associated
with an increased rate of podocyte detachment, a significant
reduction in podocyte density and proteinuria (Yang et al., 2015).
We then investigated whether uPECs presence were associated
with kidney allograft outcome. Thus, we followed our cohort
up to 2 years after transplantation. We found that those
uPEC+ patients at 6 months showed a significant eGFR
decline and albuminuria at 2 years follow up, in contrast to
those uPEC- allografts that maintained a stable eGFR without
albuminuria. Then, the isolation of uPECs at 6 months after
transplantation appears to be a predictor of worse long-term
graft outcomes. uPECs are an early marker of glomerular
cell turnover associated to podocyturia, prior to proteinuria
and allograft nephropathy. Moreover, we can support this
fact on 24 months available protocol biopsies, where we
observed a significantly increased mesangial matrix expansion
and IgM deposition on those allografts having uPEC+ at 6
months after transplantation. Interestingly, the uPEC+ group
showed a trend of PECs proliferation persistence at 2 years
as seen by Ki67 staining whereas, again, no activated PECs
evaluated by CD44 expression are predominant, suggesting
that these cells might be involved in a regenerative intention
instead of a pro-sclerotic role, but fail in regenerate chronic
podocyte loss as seen in aging models (Berger and Moeller,
2014; Wanner et al., 2014) or increased body size (Berger
and Moeller, 2014). In agreement with the 6 months results,
no significant differences were found regarding alloimmune
response assessed by de novo DSA monitoring, previous
history of acute rejection as well as inflammation and C4d
deposition in 24 months protocol biopsies. These findings
suggest again a non-immunological mechanism as the key
effector mechanism accounting for podocyturia and PEC
proliferation. Recently, Stegall et al. (2018) showed that renal
allografts sustain non-immunologic chronic histologic injury
by 10 years after transplantation, mainly mesangial sclerosis
and glomerulosclerosis, suggesting that new approaches are
needed to decrease late injury. Whether this pathogenic
mechanism is mainly due to low nephron number (Yang et al.,
2015), limited PEC endowment (Berger and Moeller, 2014) or
requires combination with additional factors that contribute
to glomerular hypertension and podocyte detachment requires
further investigation.
Our study has some limitations. Firstly, urine sample
contamination may difficult to efficiently assess the presence
of uPEC in all cases, but this was overcome with a rigorous
collection protocol. Secondly, due to the exploratory nature
of the study we did not assess the baseline nephron number.
Finally, 24 months protocol biopsy was not available in all
patients although clinical and analytical data was obtained
to all of them. However, our study has important strengths:
the prospective study design, the accurate assessment of the
immune response including the protocol biopsies and the
innovative approach to ascertain further mechanisms accounting
for allograft attrition.
CONCLUSION
The presence of uPECs at 6 months after kidney transplantation
translates a hidden damage that cannot be evidenced by renal
function and conventional histology. This damage is probably
due to podocyte stress that cause podocyte detachment, what
becomes a trigger for the proliferation and migration of PECs.
However, this mechanism of cell repair is insufficient if the
damage is maintained over the time (Figure 6). Of note,
these cells appear to be a non-invasive biomarker providing
contemporary and clinically relevant information. This opens
an extensive field of knowledge as a new diagnostic tool and
therapeutic target.
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